Sorin Group (BIT:SRN) won FDA approval for a the next generation of its Mitroflow bioprosthetic valves, touting new features that improve the implant’s durability be reducing calcification.
The new Mitroflow with Phospholipid Reduction Treatment lowers phospholipid content, which was found in testing to reduce calcium uptake by 99% compared with a control, according to a Sorin press release.
Mitroflow with PRT has been available in the European Union since 2011, and there have been more than 165,000 Mitroflow implants worldwide, the company noted.
SRN shares saw mild gains in today’s trading. The stock closed at $2.17 today, up 0.7%.
The FDA win is more good news for the company, which earlier this year won widened European approval to market its Perceval valve in patients over the age of 65. Sorin originally won CE Mark approval for the XL version of the Perceval valve last year.
